WASP confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B-cell homeostasis and function.

Development of hematopoietic cells depends on a dynamic actin cytoskeleton. Here we demonstrate that expression of the cytoskeletal regulator WASP, mutated in the Wiskott-Aldrich syndrome, provides selective advantage for the development of naturally occurring regulatory T cells, natural killer T cells, CD4(+) and CD8(+) T lymphocytes, marginal zone (MZ) B cells, MZ macrophages, and platelets. To define the relative contribution of MZ B cells and MZ macrophages for MZ development, we generated wild-type and WASP-deficient bone marrow chimeric mice, with full restoration of the MZ. However, even in the presence of MZ macrophages, only 10% of MZ B cells were of WASP-deficient origin. We show that WASP-deficient MZ B cells hyperproliferate in vivo and fail to respond to sphingosine-1-phosphate, a crucial chemoattractant for MZ B-cell positioning. Abnormalities of the MZ compartment in WASP(-/-) mice lead to aberrant uptake of Staphylococcus aureus and to a reduced immune response to TNP-Ficoll. Moreover, WASP-deficient mice have increased levels of "natural" IgM antibodies. Our findings reveal that WASP regulates both development and function of hematopoietic cells. We demonstrate that WASP deficiency leads to an aberrant MZ that may affect responses to blood-borne pathogens and peripheral B-cell tolerance.

[1]  M. Roncarolo,et al.  Development of lentiviral gene therapy for Wiskott Aldrich syndrome , 2008, Expert opinion on biological therapy.

[2]  L. Notarangelo,et al.  The Wiskott-Aldrich syndrome. , 2006, The Journal of allergy and clinical immunology.

[3]  S. Burns,et al.  Impaired T-cell priming in vivo resulting from dysfunction of WASp-deficient dendritic cells. , 2007, Blood.

[4]  M. Carroll,et al.  Natural IgM-mediated innate autoimmunity: a new target for early intervention of ischemia–reperfusion injury , 2007, Expert opinion on biological therapy.

[5]  A. Scheynius,et al.  Class A scavenger receptors regulate tolerance against apoptotic cells, and autoantibodies against these receptors are predictive of systemic lupus , 2007, The Journal of experimental medicine.

[6]  R. Xavier,et al.  Wiskott–Aldrich syndrome protein (WASP) and N-WASP are critical for T cell development , 2007, Proceedings of the National Academy of Sciences.

[7]  F. Candotti,et al.  The Phenomenon of Spontaneous Genetic Reversions in the Wiskott-Aldrich Syndrome: A Report of the Workshop of the ESID Genetics Working Party at the XIIth Meeting of the European Society for Immunodeficiencies (ESID). Budapest, Hungary October 4–7, 2006 , 2007, Journal of Clinical Immunology.

[8]  R. Siegel,et al.  Impaired in vitro regulatory T cell function associated with Wiskott-Aldrich syndrome. , 2007, Clinical immunology.

[9]  Albert Bendelac,et al.  The biology of NKT cells. , 2007, Annual review of immunology.

[10]  O. Danos,et al.  Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients , 2007, Gene Therapy.

[11]  S. Snapper,et al.  The Wiskott-Aldrich syndrome protein is required for the function of CD4+CD25+Foxp3+ regulatory T cells , 2007, The Journal of experimental medicine.

[12]  L. Notarangelo,et al.  WASP regulates suppressor activity of human and murine CD4+CD25+FOXP3+ natural regulatory T cells , 2007, The Journal of experimental medicine.

[13]  S. Ziegler,et al.  Wiskott-Aldrich syndrome protein is required for regulatory T cell homeostasis. , 2007, The Journal of clinical investigation.

[14]  S. Giliani,et al.  Stem cell transplantation for the Wiskott–Aldrich syndrome: a single-center experience confirms efficacy of matched unrelated donor transplantation , 2006, Bone Marrow Transplantation.

[15]  U. Pannicke,et al.  Retroviral WASP gene transfer into human hematopoietic stem cells reconstitutes the actin cytoskeleton in myeloid progeny cells differentiated in vitro. , 2006, Experimental hematology.

[16]  R. Mebius,et al.  Structure and function of the spleen , 2005, Nature Reviews Immunology.

[17]  F. Alt,et al.  WASP deficiency leads to global defects of directed leukocyte migration in vitro and in vivo , 2005, Journal of leukocyte biology.

[18]  Samantha J. Hardy,et al.  Impaired dendritic-cell homing in vivo in the absence of Wiskott-Aldrich syndrome protein. , 2005, Blood.

[19]  Samantha J. Hardy,et al.  Wiskott-Aldrich syndrome protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. , 2005, Blood.

[20]  E. Remold-O’Donnell,et al.  Phenotypic perturbation of B cells in the Wiskott–Aldrich syndrome , 2005, Clinical and experimental immunology.

[21]  W. Vainchenker,et al.  Mechanisms of WASp-mediated hematologic and immunologic disease. , 2004, Blood.

[22]  F. Candotti,et al.  Multiple patients with revertant mosaicism in a single Wiskott-Aldrich syndrome family. , 2004, Blood.

[23]  R. Proia,et al.  Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone , 2004, Nature Immunology.

[24]  R. V. van Lier,et al.  B Cells Are Crucial for Both Development and Maintenance of the Splenic Marginal Zone1 , 2004, The Journal of Immunology.

[25]  J. Kearney,et al.  Development and selection of marginal zone B cells , 2004, Immunological reviews.

[26]  F. Candotti,et al.  Differential contribution of Wiskott-Aldrich syndrome protein to selective advantage in T- and B-cell lineages. , 2004, Blood.

[27]  P. Doherty,et al.  Defects in T-cell-mediated immunity to influenza virus in murine Wiskott-Aldrich syndrome are corrected by oncoretroviral vector-mediated gene transfer into repopulating hematopoietic cells. , 2003, Blood.

[28]  E. Haddad,et al.  A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome. , 2003, Blood.

[29]  R. Steinman,et al.  Macrophages Control the Retention and Trafficking of B Lymphocytes in the Splenic Marginal Zone , 2003, The Journal of experimental medicine.

[30]  S. Aizawa,et al.  Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. , 2003, Immunity.

[31]  F. Alt,et al.  Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. , 2003, Blood.

[32]  Yasuhiko Ito,et al.  Mixed chimera status of 12 patients with Wiskott-Aldrich syndrome (WAS) after hematopoietic stem cell transplantation: evaluation by flow cytometric analysis of intracellular WAS protein expression. , 2002, Blood.

[33]  J. Cyster,et al.  Integrin-Mediated Long-Term B Cell Retention in the Splenic Marginal Zone , 2002, Science.

[34]  F. Candotti,et al.  Retrovirus-mediated WASP gene transfer corrects Wiskott-Aldrich syndrome T-cell dysfunction. , 2002, Human gene therapy.

[35]  Yann Leverrier,et al.  Cutting Edge: The Wiskott-Aldrich Syndrome Protein Is Required for Efficient Phagocytosis of Apoptotic Cells1 , 2001, The Journal of Immunology.

[36]  J. V. Stone,et al.  Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. , 2001, Blood.

[37]  W. Vermi,et al.  The spleen in the Wiskott-Aldrich syndrome: histopathologic abnormalities of the white pulp correlate with the clinical phenotype of the disease. , 1999, The American journal of surgical pathology.

[38]  R. Badolato,et al.  Monocytes from Wiskott-Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein-1 and formyl-methionyl-leucyl-phenylalanine. , 1998, Journal of immunology.

[39]  Philip R. Cohen,et al.  Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. , 1998, Immunity.

[40]  Dunn,et al.  Chemotaxis of macrophages is abolished in the Wiskott‐Aldrich syndrome , 1998, British journal of haematology.

[41]  S. Kanner,et al.  Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype. , 1997, Blood.

[42]  F. Alt,et al.  Defective B cell development and function in Btk-deficient mice. , 1995, Immunity.

[43]  F. Rosen,et al.  Nonrandom inactivation of the X chromosome in early lineage hematopoietic cells in carriers of Wiskott-Aldrich syndrome. , 1995, Blood.

[44]  K. Sullivan,et al.  A multiinstitutional survey of the Wiskott-Aldrich syndrome. , 1994, The Journal of pediatrics.

[45]  D J Rawlings,et al.  Mutation of unique region of Bruton's tyrosine kinase in immunodeficient XID mice. , 1993, Science.

[46]  M. Zachariah,et al.  Follicular shuttling of marginal zone B cells facilitates antigen transport , 2008, Nature Immunology.

[47]  A. Fischer,et al.  Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. , 2008, Blood.

[48]  S. Pillai,et al.  Marginal zone B cells. , 2005, Annual review of immunology.

[49]  R. Hardy,et al.  B cell development pathways. , 2001, Annual review of immunology.